Karyopharm Therapeutics Inc.

Symbol: KPTI

NASDAQ

1.37

USD

Market price today

  • -0.9064

    P/E Ratio

  • -0.0160

    PEG Ratio

  • 157.64M

    MRK Cap

  • 0.00%

    DIV Yield

Karyopharm Therapeutics Inc. (KPTI) Financial Statements

On the chart you can see the default numbers in dynamics for Karyopharm Therapeutics Inc. (KPTI). Companys revenue shows the average of 53.512 M which is 2.463 % gowth. The average gross profit for the whole period is 52.035 M which is 2.464 %. The average gross profit ratio is 0.987 %. The net income growth for the company last year performance is -0.134 % which equals -0.299 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Karyopharm Therapeutics Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.329. In the realm of current assets, KPTI clocks in at 233.921 in the reporting currency. A significant portion of these assets, precisely 192.103, is held in cash and short-term investments. This segment shows a change of -0.309% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0.301, if any, in the reporting currency. This indicates a difference of -52.449% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 170.919 in the reporting currency. This figure signifies a year_over_year change of 0.023%. Shareholder value, as depicted by the total shareholder equity, is valued at -136.206 in the reporting currency. The year over year change in this aspect is 7.178%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 26.962, with an inventory valuation of 3.04, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0. Account payables and short-term debt are 3.12 and 3.31, respectively. The total debt is 177.02, with a net debt of 124.13. Other current liabilities amount to 63.05, adding to the total liabilities of 376.64. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011

balance-sheet.row.cash-and-short-term-investments

897.57192.1278228.6
273.5
264
328.2
146.5
129.6
175.6
205.7
156
0.4
6.5

balance-sheet.row.short-term-investments

636.07139.2142.838.2
163.3
133.1
210.2
77.5
79.9
117.3
55.1
0
0
0

balance-sheet.row.net-receivables

132.372747.122.5
12.9
7.9
0
0
0
0
0
0
0
0

balance-sheet.row.inventory

13.6534.24.1
2.6
0.3
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

226.7311.819.82.9
0.6
1.5
6.4
2
2.1
2
2
2
0.6
0.4

balance-sheet.row.total-current-assets

1069.53233.9326.8258.1
289.5
273.7
334.6
148.4
131.6
177.6
207.8
158
1
6.9

balance-sheet.row.property-plant-equipment-net

23.054.97.41.6
2.2
3
3.9
2.2
2.8
3.5
2.8
0.2
0.3
0.3

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

1.70.30.60.6
24.2
2
2
29.4
45.4
33.9
8.7
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

39.741.323.444.9
-2.9
16.2
0.7
0.3
0.5
0.5
1.2
0
0
0

balance-sheet.row.total-non-current-assets

64.56.531.447.2
23.5
21.3
6.6
31.9
48.7
37.8
12.6
0.3
0.4
0.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

1134.03240.4358.2305.3
313.1
295
341.2
180.3
180.4
215.4
220.3
158.2
1.3
7.2

balance-sheet.row.account-payables

15.43.12.81.6
4.5
1
4.3
5.7
4.8
3.8
6.3
1.7
1.1
1.1

balance-sheet.row.short-term-debt

12.563.32.92.3
1.9
1.6
32.9
21.7
0
0
0
0.8
0.8
0.8

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

686.92170.9170.1169.3
117.9
109.9
102.7
0
0
0
0
0
0
0

Deferred Revenue Non Current

530.39132.5132.7133
73.1
4.5
4.5
0
0
0
0
0.4
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

-395.13---
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

172.276360.30.7
-6.4
41.4
0.3
0.1
11.7
11.3
6
0.3
0
0

balance-sheet.row.total-non-current-liabilities

1358.64307.2374.8385
262.2
245.2
111.1
1.4
1.7
1.9
1.2
0.4
27.3
17.8

balance-sheet.row.other-liabilities

-123.630-65.9-73.7
0
-46.4
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

25.522.8911.3
13.2
14.8
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

1487.05376.6374.8385
262.5
245.2
158
50.8
18.1
17.1
13.5
3.3
29.2
19.9

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0.05000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-5721-1487-1343.9-1178.6
-1069.6
-873.3
-673.7
-495.3
-366.1
-256.5
-138.3
-62.6
-28.6
-12.7

balance-sheet.row.accumulated-other-comprehensive-income-loss

-2.1-0.2-0.60.2
0.5
0
-0.2
-0.2
-0.3
-0.3
0
-0.3
-0.2
-0.1

balance-sheet.row.other-total-stockholders-equity

5370.0313511327.91098.8
1119.6
923.1
857.2
625
528.6
455.2
345.2
217.8
1
0.2

balance-sheet.row.total-stockholders-equity

-353.02-136.2-16.7-79.7
50.5
49.8
183.2
129.5
162.2
198.4
206.8
154.9
-27.9
-12.7

balance-sheet.row.total-liabilities-and-stockholders-equity

1134.03240.4358.2305.3
313.1
295
341.2
180.3
180.4
215.4
220.3
158.2
1.3
7.2

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

-353.02-136.2-16.7-79.7
50.5
49.8
183.2
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

1134.03---
-
-
-
-
-
-
-
-
-
-

Total Investments

636.37139.5142.838.2
187.5
135.1
212.2
106.9
125.3
151.2
63.8
0
0
0

balance-sheet.row.total-debt

696.11177173169.3
117.9
109.9
102.7
0
0
0
0
0
0
0

balance-sheet.row.net-debt

434.6124.137.8-21.2
32
-19
-15.4
-69
-49.7
-58.4
-150.6
-156
-0.4
-6.5

Cash Flow Statement

The financial landscape of Karyopharm Therapeutics Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.380. The company recently extended its share capital by issuing 1.12, marking a difference of 0.000 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 0.35 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to 7940000.000 in the reporting currency. This is a shift of -1.076 from the previous year. In the same period, the company recorded 0.53, 0, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 1.12, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011

cash-flows.row.net-income

-143.1-143.1-165.3-124.1
-196.3
-199.6
-178.4
-129
-109.6
-118.2
-75.8
-33.9
-15.9
-10.3

cash-flows.row.depreciation-and-amortization

0.530.50.60.8
1
1
0.7
0.7
0.7
0.6
0.3
0.1
0.1
0.1

cash-flows.row.deferred-income-tax

5.92-1.101.5
0.9
-1.4
0
0
0
1.8
0
0
0
0

cash-flows.row.stock-based-compensation

21.7121.735.429.8
24.4
15.3
17.3
20.4
22.3
17.1
14.2
3.8
0.7
0

cash-flows.row.change-in-working-capital

31.4131.4-20-23.2
1.4
-13.3
-0.2
33
1
4
9.7
-0.4
-0.4
1.7

cash-flows.row.account-receivables

20.1220.1-5.1-9.6
-5
-7.9
0
0
0
0
0
0
0
0

cash-flows.row.inventory

1.181.2-0.1-1.5
-2.6
-0.3
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

0.350.31.2-2.8
3.5
-3.3
-1.4
0.9
0.9
-2.4
4.5
0.7
-0.1
1.1

cash-flows.row.other-working-capital

-0.79.8-16-9.3
5.5
-1.8
1.2
32.1
0
6.4
5.2
-1
-0.3
0.5

cash-flows.row.other-non-cash-items

-9.19-2.2-0.38.1
8.4
7.2
1.4
1.2
1.2
0.7
0.1
0.1
0
0

cash-flows.row.net-cash-provided-by-operating-activities

-92.72000
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

00-0.1-5.7
-0.1
-0.2
-2.4
-0.1
-0.1
-1.4
-2.8
-0.1
-0.1
-0.4

cash-flows.row.acquisitions-net

00104.35.5
53.5
-78.7
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-159.15-159.2-226-45.2
-274.6
-178.5
-242.8
-98.4
-134.7
-305.2
-63.8
0
0
0

cash-flows.row.sales-maturities-of-investments

167.09167.1121.9192.8
221
257.1
137.5
115.5
159.4
215.9
0
0
0
0

cash-flows.row.other-investing-activites

-18.90-104.3-5.5
-53.5
78.7
0
0
0
-0.1
-0.4
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

7.947.9-104.3141.8
-53.7
78.5
-107.7
17.1
24.6
-90.8
-67
-0.1
-0.1
-0.4

cash-flows.row.debt-repayment

000-60
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

1.121.1189.89.9
161.8
46.2
145.7
74.9
50.6
92.1
112.8
113.2
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

1.121.14123.7
10.3
78.1
170.4
0.9
0.6
0.6
0.3
72.8
9.5
12

cash-flows.row.net-cash-used-provided-by-financing-activities

39.691.1193.773.6
172.1
124.3
316.1
75.7
51.2
92.7
113.1
185.9
9.5
12

cash-flows.row.effect-of-forex-changes-on-cash

-0.030-0.50
0.3
0
-0.1
0.2
-0.1
-0.1
0
0
0
0

cash-flows.row.net-change-in-cash

-83.61-83.4-60.6108.3
-41.6
12
49.3
19.3
-8.7
-92.3
-5.4
155.6
-6.1
3.1

cash-flows.row.cash-at-end-of-period

264.8652.9136.9197.4
89.1
130.7
118.7
69
49.7
58.4
150.6
156
0.4
6.5

cash-flows.row.cash-at-beginning-of-period

348.48136.3197.489.1
130.7
118.7
69.5
49.7
58.4
150.6
156
0.4
6.5
3.4

cash-flows.row.operating-cash-flow

-92.72-92.7-149.6-107.1
-160.2
-190.8
-159.1
-73.7
-84.4
-94
-51.4
-30.3
-15.5
-8.5

cash-flows.row.capital-expenditure

00-0.1-5.7
-0.1
-0.2
-2.4
-0.1
-0.1
-1.4
-2.8
-0.1
-0.1
-0.4

cash-flows.row.free-cash-flow

-92.72-92.7-149.7-112.8
-160.4
-191
-161.5
-73.8
-84.5
-95.4
-54.3
-30.3
-15.6
-8.9

Income Statement Row

Karyopharm Therapeutics Inc.'s revenue saw a change of -0.070% compared with the previous period. The gross profit of KPTI is reported to be 140.56. The company's operating expenses are 270.1, showing a change of -8.149% from the last year. The expenses for depreciation and amortization are 0.53, which is a -0.767% change from the last accounting period. Operating expenses are reported to be 270.1, which shows a -8.149% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.089% year-over-year growth. The operating income is -129.54, which shows a -0.089% change when compared to the previous year. The change in the net income is -0.134%. The net income for the last year was -143.1.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011

income-statement-row.row.total-revenue

146.03146157.1209.8
108.1
40.9
30.3
1.6
0.2
0.3
0.2
0.4
0.6
0.2

income-statement-row.row.cost-of-revenue

5.025.55.23.4
2.7
2.4
0
0
0
0
0
0
0
0

income-statement-row.row.gross-profit

141.01140.6151.9206.4
105.4
38.5
30.3
1.6
0.2
0.3
0.2
0.4
0.6
0.2

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

138.67---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

131.88---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-0.36-0.4-0.1-0.1
0.2
-0.1
0
-0.1
0
0
0
0
0
0

income-statement-row.row.operating-expenses

270.55270.1294.1304.7
277.2
227.8
210.2
132.1
110.9
119.3
76.1
34.3
16.5
10.5

income-statement-row.row.cost-and-expenses

275.57275.6299.3308.1
279.9
230.2
210.2
132.1
110.9
119.3
76.1
34.3
16.5
10.5

income-statement-row.row.interest-income

10.9410.92.40.6
2.8
5.4
4
1.7
1.3
0.9
0.1
0
0
0

income-statement-row.row.interest-expense

23.8223.82526
27.1
15.6
2.5
-1.6
-1.3
-0.9
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-6.95-13.2-22.7-25.5
-24.1
-10.3
1.5
-0.1
0
0
0
0
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-0.36-0.4-0.1-0.1
0.2
-0.1
0
-0.1
0
0
0
0
0
0

income-statement-row.row.total-operating-expenses

-6.95-13.2-22.7-25.5
-24.1
-10.3
1.5
-0.1
0
0
0
0
0
0

income-statement-row.row.interest-expense

23.8223.82526
27.1
15.6
2.5
-1.6
-1.3
-0.9
0
0
0
0

income-statement-row.row.depreciation-and-amortization

5.580.52.30.5
3
5.4
4
0.7
0.7
0.6
0.3
0.1
0.1
0.1

income-statement-row.row.ebitda-caps

-121.1---
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-129.54-129.5-142.2-98.3
-171.8
-189.3
-179.9
-130.5
-110.7
-119.1
-75.8
-34
-15.9
-10.3

income-statement-row.row.income-before-tax

-142.78-142.8-164.9-123.8
-196
-199.6
-178.4
-128.9
-109.4
-118.2
-75.8
-33.9
-15.9
-10.3

income-statement-row.row.income-tax-expense

0.320.30.40.3
0.3
0
0
0.1
0.1
-0.9
-0.1
0
0
0

income-statement-row.row.net-income

-143.1-143.1-165.3-124.1
-196.3
-199.6
-178.4
-129
-109.6
-118.2
-75.8
-33.9
-15.9
-10.3

Frequently Asked Question

What is Karyopharm Therapeutics Inc. (KPTI) total assets?

Karyopharm Therapeutics Inc. (KPTI) total assets is 240438000.000.

What is enterprise annual revenue?

The annual revenue is 69756000.000.

What is firm profit margin?

Firm profit margin is 0.966.

What is company free cash flow?

The free cash flow is -0.808.

What is enterprise net profit margin?

The net profit margin is -0.980.

What is firm total revenue?

The total revenue is -0.887.

What is Karyopharm Therapeutics Inc. (KPTI) net profit (net income)?

The net profit (net income) is -143099000.000.

What is firm total debt?

The total debt is 177016000.000.

What is operating expences number?

The operating expences are 270101000.000.

What is company cash figure?

Enretprise cash is 52891000.000.